What's New?

As of May 2013

Research Education Updates:

Research Cancer Immunotherapy

Learn more about the potential of PD-L1 inhibition and cancer immunotherapy.

Research B-cell

Updated the site to include more information about Glycoengineering.

Pipeline Molecules Updates:

Pipeline Overview: Content Update

For more information about molecules in early-and late stage development download the new brochure.

Anti-PDL1 (MPDL3280A)

Anti-PDL1 targets, a protein expressed on the surface of cancer cells. Find out how this molecule was designed to help promote anti-tumor immune activity.

Anti-CD22 ADC (DCDT2980S)

The Anti-CD22 ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively target B-cells expressing CD22.

Anti-CD79b ADC (DCDS4501A)

The Anti-CD79b ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively bind to CD79b and minimize effects on normal cells.